Shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 49,322 shares changed hands during trading, an increase of 173% from the previous session's volume of 18,042 shares.The stock last traded at $16.82 and had previously closed at $16.24.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on NBTX shares. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Leerink Partners set a $14.00 price objective on Nanobiotix in a research note on Thursday, September 18th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $11.00.
View Our Latest Analysis on Nanobiotix
Nanobiotix Stock Up 12.9%
The business has a 50 day moving average of $8.94 and a two-hundred day moving average of $5.74.
Institutional Investors Weigh In On Nanobiotix
An institutional investor recently bought a new position in Nanobiotix stock. Jane Street Group LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 23,283 shares of the company's stock, valued at approximately $73,000. 38.81% of the stock is owned by institutional investors.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
